Mereo Biopharma 1 Limited

Incyte Corporation

Reneo Pharmaceuticals, Inc.

Aldeyra Therapeutics, Inc.

Pulmocide Limited

Relay Therapeutics, Inc.

Kiora Pharmaceuticals, Inc.

Osama Suleiman

Susana Del Rio Gancedo

Lucia Romero Perez

Cornelius Stephan Harlacher

Stewart Jones

Jiacheng Zhou

Bo Shen

Zhongjiang Jia

Emma Sharp

Dengjin Wang

Joseph A Sclafani

Julie Ann Macrae

Neil Feeder

Rachael Lee

Daniel Carper

Robert Wilson

Mark Wright

Cristina Balogh

Stephen Gitu Machatha

André Lescarbeau

Suzanne Buttar

John Mykytiuk

Amanda Buist

Stefan Sperl

Joseph Stephen Harris

Gerald Steele

Julian Northen

Thomas Kendall

Jethro Beamish-cook

Aaron Dumas

Eden Fucci

Elisabeth Isaak

Piera Trinchera

Kate Wittering

Oleksandr Zhurakovskyi

Lisa Plasser

Christopher Daniel Scott

Zoe Prentice

Christopher John Wallis

Jamie Marshall

The invention relates to crystalline polymorphic manifestations of a compound of formula (I) and related aspects.

Polymorphs of triazole antifungal compound PC945

This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof

The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.

Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor

The disclosure is in part directed to crystalline forms of N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide represented by the following structure: its salts, its cocrystals, and variants thereof.

FGFR inhibitors and methods of making and using the same

This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR&#x3b4; agonist compound.

Crystalline PPAR&#x3b4; agonist

This invention relates to a process for the preparation of Form A of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. Also disclosed herein is Form A of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide, or pharmaceutical compositions thereof, obtainable by the process described herein.

Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

Crystalline PPAR-delta agonist

This invention relates to a process for the preparation of Form B of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide. Also disclosed herein is Form B of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide, or pharmaceutical compositions thereof, obtainable by the process described herein.

Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions, in which aldehyde toxicity is implicated in the pathogenesis, by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.

Polymorphic compounds and uses thereof

Growing community of inventors

Cambridge, United Kingdom

Osama Suleiman